Fabio Gratton, Ignite
Everyone wants to be a market leader and innovator, but no one wants to take a risk that could cost them their job. While there is a tremendous interest in strategies that leverage Web 2.0, we have yet to see the kind of traction one might expect given the surrounding media frenzy and accompanying client demand. Most of it is very safe, and does not fully take advantage of what Web 2.0 is all about-collaboration, community, and consumer-generated content.
Everyone wants to be a market leader and innovator, but no one wants to take a risk that could cost them their job. While there is a tremendous interest in strategies that leverage Web 2.0, we have yet to see the kind of traction one might expect given the surrounding media frenzy and accompanying client demand. Most of it is very safe, and does not fully take advantage of what Web 2.0 is all about—collaboration, community, and consumer-generated content.
If a client is interested in exploring a video syndication strategy on a video-sharing Web site like YouTube, the agency needs to be able to properly present the risks and benefits of this tactic. It also needs to be able to effectively articulate for the various company stakeholders (medical, legal, regulatory, IT, brand, PR, privacy, compliance, etc.) the legal and logistical concerns that might arise from embarking on this type of initiative.
What if an idea centers on re-purposing an already existing TV spot? What does this mean then to the text size and context of the fair-balance language that goes with this spot? Since videos can and should be tagged with keywords in order to be found via the site's search engine, what types of keywords are appropriate; how should these be handled from a regulatory perspective? And if "related-videos" might appear alongside the posted video, what is the risk to the company if those accompanying videos present off-label or inappropriate content? Should the ability for people to post comments be open and unmoderated, or should this functionality be "turned off," and what are the options and implications? What resources will be necessary to manage this?
The Skinny
Ignite Health is a full-service healthcare marketing agency
Telephone: 949-861-3200
E-mail: Fabio@ignitehealth.com
Web site: ignitehealth.com
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Grants Priority Review to Regeneron’s Eylea for Macular Edema Following Retinal Vein Occlusion
April 18th 2025Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks achieved non-inferior visual acuity outcomes compared to Eylea in patients with macular edema following retinal vein occlusion.
